Company intelligence / Profile preview

Impact Market

Ownership: Private
Development stage: Other

Overview

ImPact Biotech’s Padeliporfin VTP platform has demonstrated promising early results in several solid tumor types, including UTUC, esophageal, lung, and pancreatic cancers. The company received FDA Orphan Drug Designation for Padeliporfin VTP in pancreatic cancer and is accelerating programs into the clinic based on established safety and efficacy profiles from earlier research in low-risk prostate cancer.

Therapeutic areas: Oncology
Modalities: Small moleculePhotodynamic therapy
Industry: Biotech

Partnerships

The Weizmann Institute of Science [Israel]Memorial Sloan Kettering Cancer Center [US]

Beyond the preview

Go deeper on Impact Market.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Impact Market.

Explore the full profile